← Leaderboards
Philip Abbosh
Research Inst Of Fox Chase Can Ctr
$2,447,546
Attributed
$2,447,546
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $422.3K · FY2017–25$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,447,546 · 2
By mechanism
U01$2,009,718 · 1
R21$437,828 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Mutation”
- Leonard Freedman · Leidos Biomedical Research, Inc.$85,874,322
- John Damon Chodera · Sloan-Kettering Inst Can Research$48,421,310
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$38,744,543
- Lynn Briscoe · Leidos Biomedical Research, Inc.$38,032,945
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- James Dale Berry · Brigham And Women'S Hospital$19,118,191
Research focus
MutationProceduresIn Complete RemissionMuscleNext Generation SequencingPathologicFox Chase Cancer CenterImmunotherapyInterestMalignant Neoplasm Of Urinary BladderNeoadjuvant TherapyAlgorithmsOperative Surgical ProceduresCohortClinical TrialsCancer PatientChemotherapyGenesBiological MarkersCisplatinLifeCellsBiopsyProspective
Grant awards (7)
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients$422,144
U01 · FY2025 · CA · contact PI
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients$337,277
U01 · FY2024 · CA · contact PI
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients$413,702
U01 · FY2023 · CA · contact PI
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients$414,249
U01 · FY2022 · CA · contact PI
Optimization of urinary DNA deep sequencing tests to enhance clinical staging of bladder cancer patients$422,346
U01 · FY2021 · CA · contact PI
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients$238,815
R21 · FY2018 · CA · contact PI
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients$199,013
R21 · FY2017 · CA · contact PI